The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment patterns of care assessed by reason for therapy
Timeframe: 5 years
Treatment patterns of care assessed by category of diagnosis at time of therapy initiation
Timeframe: 5 years
Treatment patterns of care assessed by onset of treatment/prophylaxis
Timeframe: 5 years
Treatment patterns of care assessed by length of treatment/prophylaxis
Timeframe: 5 years
Treatment patterns of care assessed by use of diagnostic method(s)
Timeframe: 5 years
Treatment patterns of care assessed by type of diagnostic method(s) used
Timeframe: 5 years
Treatment patterns of care assessed by use of therapeutic drug monitoring (TDM)
Timeframe: 5 years
Treatment patterns of care assessed by occurrence of drug-drug interactions (DDI)
Timeframe: 5 years
Treatment patterns of care assessed by the sequence of invasive fungal infection treatment (IFI)
Timeframe: 5 years
Treatment patterns of care assessed by discontinuation due to adverse events (AEs) or other reasons
Timeframe: 5 years
Patient characteristics assessed by underlying host/risk factors
Timeframe: 5 years
Patient characteristics assessed by patient baseline characteristics
Timeframe: 5 years
Patient characteristics assessed by fungal disease diagnosis
Timeframe: 5 years
Patient characteristics assessed by pathogen treated
Timeframe: 5 years
Patient characteristics assessed by pathogen susceptibility
Timeframe: 5 years
Patient characteristics assessed by site of fungal infection
Timeframe: 5 years